Longeveron Inc. (LGVN): Price and Financial Metrics

Longeveron Inc. (LGVN): $8.05

0.40 (+5.23%)

POWR Rating

Component Grades













Add LGVN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where LGVN ranks best; there it ranks ahead of 80.41% of US stocks.
  • The strongest trend for LGVN is in Growth, which has been heading down over the past 108 days.
  • LGVN ranks lowest in Stability; there it ranks in the 2nd percentile.

LGVN Stock Summary

  • Longeveron Inc's stock had its IPO on February 12, 2021, making it an older stock than merely 0.47% of US equities in our set.
  • With a price/sales ratio of 111.44, Longeveron Inc has a higher such ratio than 97.8% of stocks in our set.
  • In terms of volatility of its share price, LGVN is more volatile than 99.55% of stocks we're observing.
  • Stocks that are quantitatively similar to LGVN, based on their financial statements, market capitalization, and price volatility, are VLDR, VUZI, AXON, AFRM, and TTD.
  • To check out Longeveron Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001721484.

LGVN Stock Price Chart Interactive Chart >

Price chart for LGVN

LGVN Price/Volume Stats

Current price $8.05 52-week high $45.00
Prev. close $7.65 52-week low $2.84
Day low $7.63 Volume 154,200
Day high $8.17 Avg. volume 3,549,459
50-day MA $9.15 Dividend yield N/A
200-day MA $8.26 Market Cap 168.34M

Longeveron Inc. (LGVN) Company Bio

Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.

LGVN Latest News Stream

Event/Time News Detail
Loading, please wait...

LGVN Latest Social Stream

Loading social stream, please wait...

View Full LGVN Social Stream

Latest LGVN News From Around the Web

Below are the latest news stories about Longeveron Inc that investors may wish to consider to help them evaluate LGVN as an investment opportunity.

Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

Girolamo brings legal, finance and M&A experience to cell therapy companyMIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its Board of Directors. Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently servin

Yahoo | February 17, 2022

3 Moonshot Stocks For 2022

Insider trading can be highly revealing when looking for moonshot stocks to buy.

Thomas Yeung on InvestorPlace | February 16, 2022

Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer''s Focuses

No summary available.

Seeking Alpha | February 14, 2022

Two Insider Moonshots Rising on Sudden Buying

Biotech insiders are among the most important investors to pay close attention to.

Thomas Yeung on InvestorPlace | February 10, 2022

3 Stocks Insiders Are Buying on Market Turbulence

When insiders buy a stock, you should take it as a sign that they think good news is about to come out.

Thomas Yeung on InvestorPlace | January 27, 2022

Read More 'LGVN' Stories Here

LGVN Price Returns

1-mo -19.66%
3-mo 19.08%
6-mo -69.35%
1-year 21.97%
3-year N/A
5-year N/A
YTD -33.31%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.649 seconds.